AGC Inc. Q2 FY2026 earnings call

Business Portfolio Transformation Progress

• AGC began transforming its business portfolio 10 years ago, splitting operations into core and strategic businesses. Strategic businesses now account for 25% of total sales and over 50% of total group operating profit, and are positioned to drive future growth.
• High-ROCE (over 10%) strategic electronics and performance chemicals businesses will continue to be expanded, with a focus on semiconductor manufacturing products.
• Core businesses (automotive glass, architectural glass, display) have completed profitability recovery efforts and will now shift focus to enhancing operational resilience.
• Essential Chemicals Southeast Asia and Life Science are still targeted for recovery improvements.

Strategic Growth Initiatives

• For semiconductor-related materials (including EUV mask blanks, CMP slurry, and lithography lens materials), capacity will be expanded by 20-50% by 2028, with investment decisions already finalized. The company targets doubling semiconductor-related sales from ~100 billion yen to 200 billion yen by 2030, with new packaging materials to be launched by that timeframe.
• For automotive and display, the company will continue productivity improvement via dismantling low-productivity older facilities, implement value-aligned pricing, and grow higher-value, advanced functional products.
• Essential Chemicals Southeast Asia benefits from strong regional demand and expanded Thai capacity that began full operations this year. The company will leverage its regional production and stable supply advantage to strengthen customer relationships and build a consistent revenue stream.
• Life Science has ~50% of sales from biopharmaceuticals, with the remaining from small molecule and other CDMO services. The unprofitable Colorado biopharma CDMO site was closed, cutting fixed costs significantly. The company targets full Life Science profitability by 2027, with the new Yokohama site on track to start commercial production by 2027 and a long-term manufacturing agreement already secured with a leading global biopharmaceutical company.

Overall ROCE Improvement Strategy

• The company will pursue company-wide ROCE improvement via cost reduction, value-aligned pricing, disciplined capital investment, inventory reduction, and business divestment/withdrawal to optimize operating assets. Timely strategic investments for high-growth areas like advanced semiconductors will continue.

1. Architectural Glass: Net sales of 229.3 billion yen (up 18.5 billion yen year-over-year), operating profit of 8.8 billion yen (up 5.5 billion yen year-over-year). Revenue contribution comes ~10% from Asia and ~90% from Europe and the Americas. 2. Automotive: Net sales of 280.3 billion yen (up 24.6 billion yen year-over-year), operating profit of 13.3 billion yen (down 1.8 billion yen year-over-year). 3. Electronics: Net sales of 174.4 billion yen (up 6.2 billion yen year-over-year), operating profit of 18.7 billion yen (down 5.7 billion yen year-over-year). Operating profit breakdown is 30% from display and 70% from electronic materials. 4. Chemicals: Net sales of 322 billion yen (up 46.2 billion yen year-over-year), operating profit of 28.2 billion yen (up 5.6 billion yen year-over-year). Operating profit breakdown is 80% from Integrated Chemicals and 20% from Essential Chemicals Southeast Asia. 5. Life Science: Net sales of 72.3 billion yen (up 8.8 billion yen year-over-year), operating loss of 6.1 billion yen, an improvement of 5.9 billion yen year-over-year. 6. Strategic Businesses (overall): Net sales of 264.4 billion yen (up 28.7 billion yen year-over-year), operating profit of 35 billion yen (up 12 billion yen year-over-year), accounting for 54% of total group operating profit.

• Full-year 2026 overall and segment-level outlooks remain unchanged from the February announcement, after the crude oil price assumption was previously revised upward from $70 to $100 per barrel in the Q1 results. Strategic businesses are still projected to hit 560 billion yen in net sales (up 58.5 billion yen year-over-year) and 80 billion yen in operating profit (up 21.3 billion yen year-over-year).
• Full-year capex, depreciation, and R&D expenditure outlooks are unchanged, with full-year capex projected to decline 61.3 billion yen year-over-year.
• Shareholder return policy is unchanged: the company maintains a policy of stable dividends targeting a 3% dividend on equity (DOE).
• Segment-specific second half expectations:
  • Architectural Glass: Seasonal shipment increases are expected in Asia, with demand for energy-saving retrofitting in Japan. Shipments recovery in Europe will be limited by ongoing economic weakness, with continued price adjustments and cost cutting planned.
  • Automotive: Seasonal shipment declines are expected, with continued product mix improvement and productivity enhancement efforts.
  • Electronics: LCD glass substrate shipments are projected to decline slightly, with continued profitability improvement. Semiconductor-related materials (including EUV mask blanks) and optoelectronic materials (driven by seasonal smartphone demand) are expected to see increased shipments.
  • Chemicals: Electronics-focused integrated chemicals shipments will grow, and Essential Chemicals Southeast Asia will see increased shipments as the expanded Thai facility ramps up, with demand remaining firm.
  • Life Science: Small molecule and agrochemical CDMO sales will grow following facility expansion, and biopharmaceutical CDMO sales and productivity will improve.

• The ongoing Middle East situation creates uncertainty for fuel and raw material prices, though management expects the impact to full year earnings to remain limited, with sufficient materials secured for the near term and diversified procurement in place to support stable supply.
• Elevated fuel and raw material prices remain a headwind for profitability across multiple segments, including architectural glass and chemicals.
• The Middle East situation creates specific uncertainty for Essential Chemicals Southeast Asia, though current operations remain stable with raw materials secured.
• Economic downturn in Europe limits shipment recovery for architectural glass, and has contributed to higher-than-expected manufacturing costs for the automotive segment in Europe and North America, pressuring profitability.
• Yen depreciation creates a negative profit impact for the display business within the Electronics segment, due to long-standing industry practice of yen-denominated pricing.
• There is some risk of delay to the divestiture of the closed Colorado Life Science site, though management notes any delay would have only a limited impact on full year operating profit and no impact on projected net sales.

Q: First half operating profit came in above internal plan across segments; what was the segment-level performance, and did Q1 one-time factors lead to a Q2 rebound? / A: Automotive and Chemicals posted net sales upside vs plan, driven by yen depreciation and product mix for Automotive, and yen depreciation, price revisions, and stronger Southeast Asian markets for Chemicals. For operating profit, Chemicals beat plan, while Automotive and Electronics came in slightly lower: Automotive saw higher-than-expected production costs in Europe and the Americas, and the display business faced negative profit pressure from yen depreciation. The Q1 consolidation-driven one-time sales upside did not repeat in Q2, and new one-time costs were incurred in Q2, leading to stronger Q1 results than Q2. (307 words)

Q: What is the probability of hitting the full year 1.1 billion yen operating profit target for Life Science, and how much of next year's sales are already secured as orders? / A: Small molecule CDMO will see higher shipments and profit in the second half, while biopharma CDMO will see rising orders and improving productivity at Copenhagen and Heidelberg, with profit improvement concentrated in Q4. Management expects to be unprofitable through Q3, turning profitable in Q4, and still expects to hit the full year target. Approximately half of next year's projected sales are already secured as orders, with the company targeting full biopharma business profitability next year. (248 words)

Q: What is the current demand and pricing outlook for EUV mask blanks, compared to your expectations at the start of the year? / A: Customer inquiries and demand for EUV mask blanks are much stronger than expected, with current supply already tight. While full year 2026 net sales are not expected to return to 2024 levels, shipment volume is already higher than last year and will grow further next year. Pricing shifts with product grade: more advanced, higher-complexity grades command higher prices, while existing standard grades see slight price declines. The current market is shifting toward higher-grade products, which increases production costs, so the company is expanding capacity fast enough to meet rising volume and maintain profitability. (269 words)

Q: The PVC-ethylene price spread improved from Q1 to Q2 for Essential Chemicals Southeast Asia; what drove this improvement and how sustainable is it? / A: The spread improved for two key reasons: both PVC and ethylene prices rose, with PVC prices increasing faster than input costs, and the elimination of Chinese export tax rebates pushed Chinese producer prices higher, lifting overall regional market prices. While the spread has seen volatility quarter-to-date, management expects the general trend of margin recovery to continue moving forward. (163 words)